Effective Response of Intrahepatic Cholangiocarcinoma to Pembrolizumab: A Case Report
Effective Response of Intrahepatic Cholangiocarcinoma to Pembrolizumab: A Case Report
复制标题
DOI：
10.21873/anticanres.14411
复制
发表时间：
2020-07-01
影响因子：
2
通讯作者：
Yamaue, Hiroki
中科院分区：
文献类型：
--
作者：
Nakamura, Masashi;Ueno, Masaki;Yamaue, Hiroki
背景/目的：派姆单抗治疗肝内胆管细胞癌 (IHCCC) 的疗效尚未得到广泛报道。病例报告：由于已证实的微卫星不稳定性 (MSI) 高状态，我们在一名患有复发性 IHCCC 的 69 岁男性术后 18 个月开始接受派姆单抗治疗。患者获得部分缓解，18 个疗程结束时缓解率降低 82.5%。原发肿瘤的免疫染色显示肿瘤内有 PD-1+ 和 CD8+ T 细胞浸润，以及 PD-L1 低表达。结论：PD-1+ 和 CD8+ T 细胞的瘤内浸润可能是派姆单抗疗效的预测因素。 PD-L1 的表达与治疗效果无关，但该患者复发性病变的肿瘤微环境可能已被常规化疗和 CD8+ T 细胞改变。
Background/Aim: The efficacy of pembrolizumab for intrahepatic cholangiocellular carcinoma (IHCCC) is not widely reported. Case Report: We began pembrolizumab treatment in a 69-year-old male with recurrent IHCCC at 18 months after his surgery because of the proven microsatellite instability (MSI)-high status. The patient had partial response, with an 82.5% reduction at the end of 18 courses. Immunostaining of the primary tumor revealed intra-tumoral infiltration of both PD-1+ and CD8+ T cells, and a low expression of PD-L1. Conclusion: Intra-tumoral infiltration of both PD-1+ and CD8+ T cells may be a predictive factor of the efficacy of pembrolizumab. Expression of PD-L1 did not correlate with a therapeutic effect, but the tumor microenvironment of our patient's recurrent lesions may have been modified by conventional chemotherapy and CD8+ T cells.